Vivek Ra­maswamy bags $100M in risk cap­i­tal to back his lat­est PhI­II gam­ble at Der­ma­vant — while Urovant dives in­to gene ther­a­py

Just a few days af­ter clos­ing on a $330 mil­lion deal with Glax­o­SmithK­line to reel in a Phase III-ready drug for the crowd­ed R&D field of pso­ri­a­sis and atopic der­mati­tis, Vivek Ra­maswamy’s Der­ma­vant inked a $100 mil­lion fi­nanc­ing deal to help pay for the next step in the clin­ic.

And that’s not all. The biotech fi­nancier al­so brought in an­oth­er key play­er for his Roivant um­brel­la or­ga­ni­za­tion, re­cruit­ing an in­vest­ment chair from NEA. And an­oth­er one of his com­pa­nies — Urovant — just in-li­censed a gene ther­a­py for over­ac­tive blad­ders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER